MedTrace Logo

Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

NCT02859012 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-05-29

No results posted yet for this study

Summary

To understand efficacy of axitinib in recurred or metastatic adenoid cystic carcinoma

Conditions

  • Recurrent ACC, metastaticACC, Unreaectable ACC

Interventions

DRUG

Axitinib

Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)

OTHER

Observation

this group is observational ones.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Bhumsuk Kim, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2020-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02859012 on ClinicalTrials.gov